Olvi-Vec clinical trials
Olvi-Vec is named as an intervention in 2 current clinical trials in our USA and China registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Genelux Corporation (1). The most-studied condition is Advanced Non-squamous Non-small-cell Lung Cancer.
Patient leaflets for Olvi-Vec
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Olvi-Vec
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
NCT06463665 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
|
Phase 2 | Recruiting | Genelux Corporation | USA |
|
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
NCT07136285 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage
|
Phase 1/2 | Recruiting | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Olvi-Vec
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Genelux Corporation | 1 |
| Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Olvi-Vec trials
How many clinical trials are testing Olvi-Vec?
2 current trials in our USA and China registers name Olvi-Vec as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Olvi-Vec trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Olvi-Vec clinical trials?
Genelux Corporation (1) and Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Olvi-Vec works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Olvi-Vec works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Olvi-Vec (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.